Browsing Tag
KRAS Inhibitors
4 posts
Could oral elraglusib emerge as a combination backbone for RAS-targeted cancer therapies?
Actuate Therapeutics, Inc. is advancing oral elraglusib to target resistance biology in cancer. Discover what this means for oncology markets.
Can KST-6051 unlock broader KRAS cancer treatment beyond G12C inhibitors
KST-6051 enters Phase 1 with AbbVie Inc. backing. Discover how pan-KRAS inhibitors could expand treatment across KRAS-driven cancers.
Jacobio Pharma secures $2bn global licensing agreement with AstraZeneca for JAB-23E73
Jacobio Pharma’s $2B global licensing deal with AstraZeneca could reshape KRAS inhibitor strategy in oncology. Read the full breakdown of the partnership now.
Jazz Pharmaceuticals to acquire Redx Pharma’s KRAS inhibitor program to expand oncology pipeline
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) have entered into a definitive agreement, marking…